• Hristina Hitkova Medical University-Pleven Author
  • Diana Georgieva Microbiology Laboratory, Hospital „Hеart and Brain”, Pleven, Bulgaria. Author




vulvovaginal candidiasis, antifungal agents, Candida species


Introduction: Vulvovaginal candidiasis (VVC) is the most common Candida infection in females of reproductive age. Data concerning the species identification and antifungal susceptibility of vaginal Candida isolates are of great importance for the infection management.

Aim: The aim of the present study was to determine the species distribution and antifungal susceptibility of Candida isolates obtained from vaginal samples of women with VVC.

Material and methods: A total of 125 vaginal Candida isolates were collected and tested. The definitive species identification was performed by VITEC2 Compact (Bio Merieux, France) using YST ID cards. The minimum inhibitory concentrations (MICs) of nine antifungal agents were determined by the commercial system Micronaut-AM (Merlin Diagnostika GmbH, Germany).

Results: Overall, 8 Candida species were established among the vaginal yeast isolates. The most common was C. albicans (77.6%), followed by C. glabrata (12%), C. krusei (4%), C. kefyr (2.4%), C. spherica (1.6%), C. lusitaniae, C. utilis, and C. sake (each one 0.8%). All C. albicans and 20 non-albicans Candida (NAC) were susceptible to nine antifungal agents. In the group of NAC, 8 isolates were resistant to fluconazole – 5 C. krusei with intrinsic resistance, 2 C. spherica, and 1 C. sake. The fluconazole MICs of C. spherica and C. sake were 32 - 128 μg/mL, and 16 μg/mL, respectively.

Conclusions: C. albicans was the main causative agent of VVC. Among NAC, C. glabrata was the predominant species. In general, vaginal C. albicans and non-albicans Candida were susceptible to azoles as well as echinocandins, amphotericin B and 5-fluorocytosine. Of particular interest was the detection of rare non-albicans Candida isolates with acquired resistance to azoles.


Download data is not yet available.


Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol. 2009; 144(1):68–71. https://doi.org/10.1016/j.ejogrb.2008.12.020

Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG Int J Obstet & Gynaecol. 2015; 122(6):785–794. https://doi.org/10.1111/1471-0528.12994

Chatzivasileiou P, Vyzantiadis TA. Vaginal yeast colonisation: From a potential harmless condition to clinical implications and management approaches-a literature review. Mycoses. 2019; 62(8):638–650. https://doi.org/10.1111/myc.12920

Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol. 2006;126(1):121–125. https://doi.org/10.1016/j.ejogrb.2005.09.015

Holland J, Young ML, Lee O, Chen SC-A. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect. 2003; 79:249–250. https://doi.org/10.1136/sti.79.3.249

Farr A, Effendy I, Frey Tirri B, Hof H, Mayser P, Petricevic L., Ruhnke M, Schaller M, Schaefer APA, Sustr V, Willinger B, Mendling W. Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses. 2021; 64 (6):583–602. https://doi.org/10.1111/myc.13248

Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol. 2006; 44(9):3213–3217. https://doi.org/10.1128/JCM.00218-06

Tsega A. Mekonnen F. Prevalence, risk factors and antifungal susceptibility pattern of Candida species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia. BMC Pregnancy & Childbirth. 2019; 19(1):527–528. https://doi.org/10.1186/s12884-019-2494-1

Willems HM, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020; 6(1):27. https://doi.org/10.3390/jof6010027

Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Yazdani Cherati J, Mosayebi E. Isolation of different species of Candida in patients with vulvovaginal candidiasis from Sari, Iran. Jundishapur J Microbiol. 2015; 8(4):e15992. https://doi.org/10.5812/jjm.8(4)2015.15992

Priscilla R, Kumari P, Ahmad SN. Isolation and identification of Candida Species in Patients with Vulvovaginal Candidiasis. Int J Adv Microbiol Health Res. 2021; 5(1):1–7. www.ijamhr.com

Waikhom SD, Afeke I, Kwawu GS, Mbroh HK, Osei GY, Louis B, Deku JG , Kasu ES, Mensah P, Agede CY, Dodoo C, Asiamah EA, Tampuori J, Korbuvi J, Opintan JA. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates. BMC Pregnancy & Childbirth. 2020; 20:266 https://doi.org/10.1186/s12884-020-02963-3

The European Committee on Antimicrobial Susceptibility Testing. Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures. Version 4.0, 2023. http://www.eucast.org

Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018; 19(9):971–977. https://doi.org/10.1080/14656566.2018.1476490

Klesiewicz K, Mrowiec P, Kania K, Skiba-Kurek I, Białecka J, Namysł M, Małek M. Prevalence of closely related Candida albicans species among patients with vulvovaginal candidiasis in Southern Poland based on the hwp 1 gene amplification. Pol J Microbiol. 2023; 72(1):69–77. https://doi.org/10.33073/pjm-2023-011

Wójkowska-Mach J, Pomorska-Wesołowska M, Romanik M, Romaniszyn D. Prevalence and antimicrobial susceptibility profiles of microorganisms associated with lower reproductive tract infections in women from Southern Poland – retrospective laboratory-based study. Int J Environ Res Public Health. 2021; 18(1):335. https://doi.org/10.3390/ijerph18010335

Mohammadi F, Hemmat N, Bajalan Z, Javadi A. Analysis of biofilm-related genes and antifungal susceptibility pattern of vaginal Candida albicans and non-Candida albicans species. Biomed Res Int. 2021; 5598907. https://doi.org/10.1155/2021/5598907

Tseng Y-H, Lee W-T, Kuo T-C. In-vitro susceptibility of fluconazole and amphotericin B against Candida isolates from women with vaginal candidiasis in Taiwan. J Food Drug Anal. 2005; 13,(1):12–16. https://doi.org/10.38212/2224-6614.2547

Nouraei S, Sharifi F, Shahverdi E, Konjedi MA. The Prevalence of Symptomatic Vaginal Candidiasis Among Females in Tehran., Biotech Health Sci. 2014; 3(2):e34642. https://doi.org/10.17795/bhs-34642

Kan S, Song N, Pang Q, Mei H, Zheng H, Li D, Cui F, Lv G, An R, Li P, Xiong Z, Fan S, Zhang M, Chen Y, Qiao Q, Liang X, Cui M, Li D, Liao Q, Li X, Liu W. In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China. Mycopathologia. 2023; 188(1-2):99–109. https://doi.org/10.1007/s11046-022-00687-w

Chokoeva A, Kouzmanov A, Ivanova Z, Zisova L, Amalie G, Petleshkova P, Miteva-Katrandzhieva T, Krasteva M, Uchikova E. Investigation of antifungal susceptibility of Candida yeasts in pregnant patients with confirmed vulvovaginal candidiasis and their newborns. Akush Ginekol (Sofia). 2016; 55(4):20–29. (Bulgarian).PMID: 29370489







How to Cite

Hitkova, H.; Georgieva, D. SPECIES DISTRIBUTION AND ANTIFUNGAL SUSCEPTIBILITY OF VAGINAL CANDIDA ISOLATES. Probl Infect Parasit Dis 2024, 52 (1), 13-17. https://doi.org/10.58395/2enj2697.